Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. We also use them to share. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. 124. com uses cookies on this site. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Clinical-stage pharmaceutical company Theralase Technologies Inc. We also use them to share usage. L. Senior Director, Investor Relations. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. org. Further. Track Theratechnologies Inc. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. 521. The business had revenue of $27. . - TH1902 Phase 1 basket trial proceeding as planned. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. (THTX) Stock Price, Quote & News - Stock Analysis -20. MONTREAL, Oct. Watch list NEW Set a price target alert After Hours Last. MONTREAL, March 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Appoints New Board Member. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. 1-438. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. We also use them to share usage. (TSX:TH) announced new data from a tissue microarrays study which demonstrated high expression of sortilin 1 in solid tumors. com. com. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Oct. Unveiling Silvercorp's golden potential at the Ying Mining District. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. is a pharmaceutical company. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. Heures de négociation. By continuing to use our service, you agree to our use of cookies. Stockhouse. Website. Stockhouse. Stockhouse. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. Contact Email communications@theratech. Theratechnologies layoffs. About Theratechnologies. Register for your free account today at data. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Message Board Total Posts: 4. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. com. R. MONTREAL, Sept. Theratechnologies Stock Price, News and Company Updates. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. com uses cookies on this site. (2021-05-31 | TSX:TH) Theratechnologies Hires Vice President, Human Resources. com uses cookies on this site. e. This news release constitutes a “designated news release” for the purposes of the Company’s. Theratechnologies Inc. 40%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. com uses cookies on this site. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. Senior Director, Investor Relations. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 08). Theratechnologies Inc. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 06 million, an increase of. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. 4% annually. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. . -4. ( THTX 3. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. The business had revenue of $27. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Volume has increased on the last day along with the price, which is a. Montréal, Québec, Canada . 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. MONTREAL, Feb. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. MONTREAL, Nov. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 04) earnings per share (EPS) for the quarter. 1M. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. Theratechnologies Inc. Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. During the last trading day the stock fluctuated 4. FY2022 revenue. This module allows you to check different measures of market premium (i. stock news by MarketWatch. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. This news release constitutes a “designated news release” for the purposes. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. (TH. A live webcast of Dr. 29(+0. Phone Number 15143319691. By continuing to use our service, you agree to our use of cookies. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. By continuing to use our service, you agree to our use of cookies. M. 1. Q4 2022 consolidated revenue growth of 14. Selected news for Normal, Illinois and Cancer Therapy, which are filed under Locations / US Cities and Healthcare Topics, respectively. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. We also use them to share usage information with our partners. T. GlobeNewswire. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. Further. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. Elif McDonald - Senior Director, Investor Relations. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. stock news by MarketWatch. MONTREAL, Aug. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. 17. 4% from the stock's current price. A high-level overview of Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. TH | Complete Theratechnologies Inc. Stockhouse. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. Theratechnologies stated the primary endpoint measured a 90 per cent confidence interval of the IM injection to IV injection (0. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. By continuing to use our service, you agree to our use of cookies. This news release constitutes a “designated news release” for the purposes of the Company’s. MONTREAL, Dec. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. This news release constitutes a "designated news release" for the purposes of. Investor Relations. com uses cookies on this site. The firm offers its product under the brand name of EGRIFTA, which is an approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. 4. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Visit the TSX ETF Investor Centre to access our screener and comparison tool. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. According to 3 analysts, the average rating for THTX stock is "Buy. The abstracts are now available at aacr. VANCOUVER, British Columbia, Nov. We currently market prescription products for people with HIV in the United States. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. 00. m. ir@theratech. (TH. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. By continuing to use our service, you agree to our use of cookies. Theratechnologies Announces 1-for-4 Reverse Stock Split. Shares of Theratechnologies are up 4. (TSX: TH, Forum) has long been a favourite among Healthcare Bullboard posters who have been following its developments to commercialize innovative therapies. . Theratechnologies Inc. Stockhouse. Saint-Laurent, Canada. Theratechnologies Inc. Theratechnologies Inc. VANCOUVER, British Columbia, Nov. Company Type For Profit. The firm offers its product under the brand name of. T. TH1902 combines Theratechnologies’ proprietary peptide to. com uses cookies on this site. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 5%. 5000 0. The abstract and poster can be found on Theratechnologies’ website. Who is Theratechnologies. 31K. 33. Follow. TH | May 19, 2023. Theratechnologies, Inc. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. By continuing to use our. These pharmaceuticals. By continuing to use our service, you agree to our use of cookies. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. 74M. 4 million. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected]%) S&P 500. We also use them to share usage information with our partners. We also use them to share usage. Whether TH1902 impacts the chemoresistance phenotype of human triple-negative breast CSC. 8 million. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. . (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. By continuing to use our service, you agree to our use of cookies. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. T. By continuing to use our service, you agree to our use of cookies. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. During the last trading day the stock fluctuated 12. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. MONTREAL, Feb. For investor inquiries: Leah Gibson. com uses cookies on this site. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. NEW YORK, Dec. T. Montréal, Québec, Canada . THERATECHNOLOGIES INC. By continuing to use our service, you agree to our use of cookies. MONTREAL, Oct. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Gary Littlejohn. ET. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. S. Remember, high Theratechnologies' alpha is almost always a sign of. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 35 as of 10:41 a. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). MONTREAL, Dec. Headquarters. 0. Free cash flow. NCU. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. We also use them to share usage information with our partners. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. 617-356-1009. Theratechnologies Inc. znewcar1. We also use them to share. La Bourse de Toronto a perdu. Cookies are used to offer you a better browsing experience and to analyze our traffic. 08 (+6. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. View real-time stock prices and stock quotes for a full financial overview. Theratechnologies Inc. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. The company was. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. We also use them to share. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". 24 million, 48. MONTREAL, Jan. We also use them to share usage. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. stock news by MarketWatch. Vice President, Communications and Corporate Affairs. 514-336-7800. 25 to $1. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. 617-356-1009. (882) posted 3 minutes ago. 86%. The FDA granted fast track designation to TH1902 as a single agent for. com uses cookies on this site. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. TH | July 20, 2023. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. 71. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. lgibson. com. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. - Cash, bonds and money market funds of US$22. . (2013-04-03 | TSX:TH) Theratechnologies Inc. 51 S1. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. com uses cookies on this site. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. Theratechnologies's earnings have been declining at an average annual rate of -35. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. 9 million, adjusted EBITDA of $2. FY2023 revenue guidance range set between $90 million and $95 million. We also use them to share usage. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Losses were -47.